Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06994650). This is a study registration, not published results. Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 144 participants (ACTUAL). Conditions: Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy. Interventions: DRUG: HRS9531; DRUG: Placebo. Primary outcome measures: The change of AHI form baseline after 52 weeks of treatment , 52 weeks. Brief summary: This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.